Citius Pharma's Q2 Loss Widens Amid R&D Spend

Ticker: CTXR · Form: 10-Q · Filed: Aug 12, 2025 · CIK: 1506251

Sentiment: bearish

Topics: Biotechnology, Pharmaceuticals, Clinical Trials, Net Loss, R&D Expenses, Pre-Revenue, Nasdaq

Related Tickers: CTXR

TL;DR

**CTXR is burning cash with no revenue, making it a high-stakes bet on pipeline success.**

AI Summary

Citius Pharmaceuticals, Inc. (CTXR) reported no revenue for the quarter ended June 30, 2025, consistent with its pre-commercial stage as a pharmaceutical company. The company incurred a net loss of $10.5 million for the three months ended June 30, 2025, an increase from a net loss of $9.2 million for the same period in 2024, primarily due to increased research and development expenses. Key business changes include continued advancement of its late-stage product candidates, particularly Mino-Lok, which is in Phase 3 clinical trials. Risks highlighted include the inherent uncertainties of clinical trials, the need for significant additional capital to fund operations and clinical development, and the potential for delays in regulatory approvals. The strategic outlook focuses on progressing its pipeline through clinical development and seeking regulatory approvals to bring its innovative therapies to market.

Why It Matters

For investors, CTXR's widening net loss to $10.5 million signals continued cash burn in its pre-revenue stage, emphasizing the high-risk, high-reward nature of biotech investments. Employees face the pressure of successful clinical trial execution and regulatory milestones to secure the company's future. Customers, particularly patients awaiting new treatments, are directly impacted by the pace and success of CTXR's drug development, especially for its lead candidate, Mino-Lok. In the competitive pharmaceutical landscape, CTXR's ability to secure funding and achieve regulatory approval for its unique therapies will determine its long-term viability and market share against larger, more established players.

Risk Assessment

Risk Level: high — The company reported no revenue for the quarter ended June 30, 2025, and a net loss of $10.5 million, indicating significant cash burn without commercial products. As a pre-commercial pharmaceutical company, CTXR's future is entirely dependent on the successful development and regulatory approval of its drug candidates, which is inherently uncertain and costly.

Analyst Insight

Investors should approach CTXR with caution, recognizing it as a speculative investment tied to clinical trial outcomes. Monitor progress on Mino-Lok's Phase 3 trial and the company's cash position closely, as further dilution or financing challenges are likely before any potential revenue generation.

Financial Highlights

debt To Equity
N/A
revenue
$0
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
-$10.5M
eps
N/A
gross Margin
N/A
cash Position
N/A
revenue Growth
N/A

Key Numbers

Key Players & Entities

FAQ

What was Citius Pharmaceuticals' net loss for the quarter ended June 30, 2025?

Citius Pharmaceuticals, Inc. reported a net loss of $10.5 million for the quarter ended June 30, 2025, which is an increase from the $9.2 million net loss reported for the same period in 2024.

Did Citius Pharmaceuticals generate any revenue in Q2 2025?

No, Citius Pharmaceuticals, Inc. reported no revenue for the quarter ended June 30, 2025, consistent with its status as a pre-commercial stage pharmaceutical company.

What is the primary reason for the increased net loss at Citius Pharmaceuticals?

The primary reason for the increased net loss at Citius Pharmaceuticals, Inc. is higher research and development expenses, as the company continues to advance its product pipeline, including the Mino-Lok Phase 3 clinical trial.

What is Citius Pharmaceuticals' lead product candidate and its current development stage?

Citius Pharmaceuticals' lead product candidate is Mino-Lok, which is currently in Phase 3 clinical trials. This product is critical for the company's future commercial prospects.

What are the main risks for investors in Citius Pharmaceuticals?

The main risks for investors in Citius Pharmaceuticals, Inc. include the inherent uncertainties of clinical trials, the significant need for additional capital to fund operations, and potential delays in regulatory approvals for its drug candidates.

How does Citius Pharmaceuticals plan to fund its operations given its net loss?

Citius Pharmaceuticals, Inc. will need to secure significant additional capital through equity offerings, debt financing, or strategic partnerships to fund its ongoing operations and advance its clinical development programs, as it currently generates no revenue.

Is Citius Pharmaceuticals considered a 'smaller reporting company' by the SEC?

Yes, Citius Pharmaceuticals, Inc. has indicated in its 10-Q filing that it is a 'smaller reporting company' as defined in Rule 12b-2 of the Exchange Act.

What exchange is Citius Pharmaceuticals' common stock traded on?

Citius Pharmaceuticals, Inc.'s common stock, with a $0.001 par value, is traded on the Nasdaq Capital Market under the trading symbol CTXR.

What is the long-term strategic outlook for Citius Pharmaceuticals?

The long-term strategic outlook for Citius Pharmaceuticals, Inc. is focused on successfully progressing its pipeline through clinical development, achieving regulatory approvals, and ultimately commercializing its innovative therapies to address unmet medical needs.

What impact do increased R&D expenses have on Citius Pharmaceuticals' financial health?

Increased R&D expenses, contributing to a $10.5 million net loss in Q2 2025, directly impact Citius Pharmaceuticals' financial health by increasing its cash burn and necessitating further capital raises to sustain operations and clinical trials.

Risk Factors

Industry Context

Citius Pharmaceuticals operates in the highly competitive pharmaceutical sector, focusing on developing innovative therapies. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight from bodies like the FDA. Success hinges on navigating complex clinical trials and securing market approval against established treatments and emerging competitors.

Regulatory Implications

The company's progress is intrinsically tied to regulatory approvals. Successful completion of Phase 3 trials for Mino-Lok is a prerequisite for seeking FDA approval. Any delays or adverse findings in these trials could significantly postpone or prevent market entry, impacting the company's financial outlook and investor confidence.

What Investors Should Do

  1. Monitor Mino-Lok Phase 3 trial progress and results closely.
  2. Assess the company's ability to secure future financing.
  3. Evaluate the competitive landscape for Mino-Lok's target indication.

Key Dates

Glossary

Pre-commercial stage
A phase in a pharmaceutical company's lifecycle where it has not yet received regulatory approval for its products and therefore has no sales revenue from those products. (Explains why Citius Pharmaceuticals reported $0 revenue and relies on financing for operations.)
Phase 3 clinical trials
The stage of clinical research where a drug is tested on a large group of patients to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug to be used safely. (Indicates that Mino-Lok is in a critical, late-stage trial, the results of which will heavily influence its potential for regulatory approval and commercialization.)
Net loss
The total expenses of a company exceed its total revenues over a specific period. (Highlights the company's current financial performance, showing an increase in losses due to R&D spending.)

Year-Over-Year Comparison

For the quarter ended June 30, 2025, Citius Pharmaceuticals reported $0 in revenue, consistent with its pre-commercial status, and a net loss of $10.5 million. This represents an increase in net loss compared to the $9.2 million loss reported for the same period in 2024, primarily driven by higher research and development expenses. No new significant risks were highlighted, but the existing risks related to clinical trial success, regulatory approval, and the need for substantial future capital remain paramount.

Filing Stats: 4,432 words · 18 min read · ~15 pages · Grade level 18.1 · Accepted 2025-08-12 16:31:37

Key Financial Figures

Filing Documents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION: 1 Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets at June 30, 2025 and September 30, 2024 1 Condensed Consolidated Statements of Operations for the Three and Nine Months Ended June 30, 2025 and 2024 2 Condensed Consolidated Statements of Changes in Stockholders' Equity for the Three and Nine Months Ended June 30, 2025 and 2024 3 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended June 30, 2025 and 2024 4 Notes to Condensed Consolidated Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 17 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 25 Item 4.

Controls and Procedures

Controls and Procedures 25

OTHER INFORMATION

PART II. OTHER INFORMATION 26 Item 1.

Legal Proceedings

Legal Proceedings 26 Item 1A.

Risk Factors

Risk Factors 26 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 26 Item 3. Defaults Upon Senior Securities 26 Item 4. Mine Safety Disclosures 26 Item 5. Other Information 26 Item 6. Exhibits 27

SIGNATURES

SIGNATURES 29 i EXPLANATORY NOTE In this Quarterly Report on Form 10-Q, and unless the context otherwise requires, the "Company," "we," "us," and "our" refer to Citius Pharmaceuticals, Inc. ("Citius Pharma") and its wholly-owned subsidiary Leonard-Meron Biosciences, Inc., and its majority-owned subsidiaries, Citius Oncology, Inc. (Nasdaq: CTOR) ("Citius Oncology") and NoveCite, Inc., taken as a whole. Mino-Lok is our registered trademark and LYMPHIR TM is a registered trademark of Citius Oncology. All other trade names, trademarks and service marks appearing in this quarterly report are the property of their respective owners. We have assumed that the reader understands that all such terms are source-indicating. Accordingly, such terms, when first mentioned in this report, appear with the trade name, trademark or service mark notice and then throughout the remainder of this report without trade name, trademark or service mark notices for convenience only and should not be construed as being used in a descriptive or generic sense. ii CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains "forward-looking strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in this Report and in other documents which we file with the Securities and Exch

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. CITIUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) June 30, September 30, 2025 2024 ASSETS Current Assets: Cash and cash equivalents $ 6,089,126 $ 3,251,880 Inventory 17,208,967 8,268,766 Prepaid expenses 1,313,176 2,700,000 Total Current Assets 24,611,269 14,220,646 Operating lease right-of-use asset, net 880,732 246,247 Deposits 38,062 38,062 In-process research and development 92,800,000 92,800,000 Goodwill 9,346,796 9,346,796 Total Other Assets 102,184,858 102,184,858 Total Assets $ 127,676,859 $ 116,651,751 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 10,094,042 $ 4,927,211 License payable 28,400,000 28,400,000 Accrued expenses 8,523,675 17,027 Accrued compensation 3,710,041 2,229,018 Note payable 1,000,000 - Operating lease liability 114,694 241,547 Total Current Liabilities 51,842,452 35,814,803 Deferred tax liability 7,506,520 6,713,800 Operating lease liability - noncurrent 766,957 21,318 Total Liabilities 60,115,929 42,549,921 Commitments and Contingencies Stockholders' Equity: Preferred stock - $ 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding - - Common stock - $ 0.001 par value; 250,000,000 and 16,000,000 shares authorized; 14,475,029 and 7,247,243 shares issued and outstanding at June 30, 2025 and September 30, 2024, respectively 14,475 7,247 Additional paid-in capital 295,888,916 271,440,421 Accumulated deficit ( 230,844,841 ) ( 201,370,218 ) Total Citius Pharmaceuticals, Inc. Stockholders' Equity 65,058,550 70,077,450 Non-controlling interest 2,502,380 4,024,380 Total Equity 67,560,930 74,101,830 Total Liabilities and Equity $ 127,676,859 $ 116,651,751 See notes to unaudited condensed consolidated financial Reflects a 1-for-25 reverse stock split effective November 25, 2024. 1 CITIU

Business

Business Citius Pharmaceuticals, Inc. ("Citius Pharma," and together with its subsidiaries, the "Company", "we" or "us") is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products and stem cell therapies. On March 30, 2016, Citius Pharma acquired Leonard-Meron Biosciences, Inc. ("LMB") as a wholly-owned subsidiary. We acquired all the outstanding stock of LMB by issuing shares of our common stock. The net assets acquired included identifiable intangible assets of $ 19,400,000 related to in-process research and development. We recorded goodwill of $ 9,346,796 for the excess of the purchase price over the net assets acquired. On September 11, 2020, we formed NoveCite, Inc. ("NoveCite"), a Delaware corporation, of which we own 75 % of the issued and outstanding capital stock (see Note 3). On August 23, 2021, we formed Citius Oncology, Inc. (formerly named Citius Acquisition Corp.) ("Citius Oncology"), as a wholly-owned subsidiary in conjunction with the acquisition of LYMPHIR, which began operations in April 2022. Pursuant to a merger agreement, dated October 23, 2023, with TenX Keane Acquisition, and its wholly owned subsidiary, TenX Merger Sub Inc ("Merger Sub"), on August 12, 2024, Merger Sub merged with and into Citius Oncology, with Citius Oncology surviving as a wholly owned subsidiary of TenX Keane Acquisition. After the merger and recapitalization (the "Merger"), the newly combined publicly traded company is owned 92.3 % by Citius Pharma, and is named "Citius Oncology, Inc." (Nasdaq: CTOR). Since our inception, we have devoted substantially all our efforts to business planning, research and development, recruiting management and technical staff, and raising capital. We are

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing